Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism
International Journal of Molecular Sciences · 08.01.2025 · 26 (2) · 465
DOI: 10.3390/ijms26020465 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.01.2025. Verfasst von Federico Gatto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, 161…. Hauptthemen laut MEDLINE: Acromegaly, Glucose. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acromegaly is a rare endocrine disorder caused by excessive growth hormone (GH) production, due, in the vast majority of cases, to the presence of a GH-secreting pituitary tumour. The chronic elevation of GH and the resulting high circulating levels of insulin-like growth factor-1 (IGF-1) cause the characteristic tissue overgrowth and a number of associated comorbidities, including several metabolic changes, such as glucose intolerance and overt diabetes mellitus (DM). Elevated GH concentrations directly attenuate insulin signalling and stimulate lipolysis, decreasing glucose uptake in peripheral tissues, thus leading to the development of impaired glucose tolerance and DM. Acromegaly treatment aims to normalize plasma GH and IGF-1 levels using surgery, medical treatment, or radiotherapy. The effect of the different medical therapies on glucose homeostasis varies. This literature review explores the impact of the currently available pharmacological therapies for acromegaly (first- and second-generation somatostatin receptor ligands, a GH receptor antagonist, and dopamine agonists) on glucose homeostasis. We also discuss the underlying biological mechanisms through which they impact glucose metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, 16132 Genova, Italy.
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
- Department of Endocrinology, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden.
ORCID-Profile: Federico Gatto, Anna Arecco, Jessica Amarù, Marica Arvigo, Claudia Campana, Angelo Milioto, Daniela Esposito, Gudmundur Johannsson, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Alessandra Puddu
Zitieren
APA
Gatto, F., Arecco, A., Amarù, J., Arvigo, M., Campana, C., Milioto, A., Esposito, D., Johannsson, G., Cocchiara, F., Maggi, D. C., Ferone, D., & Puddu, A. (2025). Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. International Journal of Molecular Sciences, 26(2), 465. https://doi.org/10.3390/ijms26020465
Vancouver
Gatto F, Arecco A, Amarù J, Arvigo M, Campana C, Milioto A, et al. Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. International Journal of Molecular Sciences. 2025;26(2):465. doi:10.3390/ijms26020465
BibTeX
@article{Gatto2025,
author = {Gatto, Federico and Arecco, Anna and Amarù, Jessica and Arvigo, Marica and Campana, Claudia and Milioto, Angelo and Esposito, Daniela and Johannsson, Gudmundur and Cocchiara, Francesco and Maggi, Davide Carlo and Ferone, Diego and Puddu, Alessandra},
title = {Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {2},
pages = {465},
doi = {10.3390/ijms26020465}
}
EUVIMED